News

Response Biomedical and Roche Diagnostics signed a strategic partnership in June 2008 to commercialize Response’s cardiovascular tests. The first project approved for funding is to complete a submission

Net loss for the full year 2008 was $93.6 million, compared to $160 million for the full year 2007. Net loss per share was $0.26 and $1.53 for

Net loss for the 12 months ended December 31, 2008 was $62.5 million, or $2.48 per diluted share, compared to a net income of $28.2 million, or $1.08

The new San Diego research facility now houses expanded research laboratories for peptide medicinal chemistry, bioanalytical and DMPK (distribution, metabolism and Pharmacokinetics), molecular and cell biology, cell culture,

The recently completed trials include both a multiple ascending dose study in subjects aged 18-55 and a separate study conducted in subjects 65 years of age or older.

These products currently include Prospera brachytherapy seeds, SurTRAK needles and strands and various accessories used primarily in the treatment of prostate cancer. North American Scientific (NASM) will receive

Under the terms of the collaboration agreement, Novelos may receive up to $25 million of launch milestones and $60 million of fixed sales-based payments. Novelos will receive a

“When many of our biopharmaceutical manufacturing customers began to establish significant operations in Asia, we saw a need,” said Millipore chairman, president and chief executive officer Martin Madaus.

The Phase II trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of bavituximab in combination with the chemotherapy drugs carboplatin and paclitaxel in